Research advances in primary biliary cholangitis
10.3760/cma.j.issn.1007-3418.2017.11.001
- VernacularTitle: 原发性胆汁性胆管炎研究进展
- Author:
Weijia DUAN
1
,
2
,
3
;
Jidong JIA
Author Information
1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University
2. Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis
3. National Clinical Research Center for Digestive Disease, Beijing 100050, China.
- Publication Type:Editorial
- Keywords:
Diagnosis;
Therapy;
Primary biliary cholangitis
- From:
Chinese Journal of Hepatology
2017;25(11):801-804
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is a chronic cholestatic disease with unknown pathogenesis. Positive anti-mitochondrial antibody has high sensitivity and specificity in the diagnosis of this disease. Ursodeoxycholic acid is mainly used for the treatment of PBC, but 40% of patients have an unsatisfactory biochemical response to this drug. 6-Ethylchenodeoxycholic acid is a new drug approved for the treatment of PBC, and liver transplantation remains the only effective method for the treatment of patients with end-stage PBC.
